Avalon GloboCare Corp. (NASDAQ: ALBT) announced a significant intellectual property milestone today, which caused its shares to jump 8.70% to $4.35 in early trade. Investor confidence following ALBT’s announcement that the company had been awarded a new patent in China for its cutting-edge cell treatment technology is reflected in the rise in share value.
A New Patent Enhances the Worldwide IP Portfolio
The patent “Artificial Immunosurveillance Chimeric Antigen Receptor and Cells Expressing the Same” was formally awarded to Avalon GloboCare and its partner, Arbele Limited, by the China National Intellectual Property Administration or CNIPA. Avalon’s worldwide patent strategy has advanced strategically with this breakthrough.
The new Chinese patent strengthens ALBT’s growing global intellectual property footprint by enhancing already-existing protections under the Patent Cooperation Treaty (PCT) in the US and other countries. The patent will remain in force for 20 years after April 4, 2025.
CAR-T and CAR-NK Cell Therapy Advancements
An important advancement in the realm of chimeric antigen receptor or CAR therapy is represented by this patent. One of its key characteristics is a bispecific anti-CD19xCD22 CAR, which targets two antigens to reduce the possibility of tumor escape due to antigen loss.
A localized cytokine induction technique intended to improve the survival, proliferation, and therapeutic effectiveness of CAR-T and CAR-Natural Killer or NK cells is also covered by the patent. Additionally, this method boosts the patient’s immune system at the tumor’s location, perhaps increasing the treatment’s overall efficacy.
Setting Up for Future Innovation
Its successful patent victory in China enhances Avalon GloboCare’s competitive position in cell-based immunotherapy and expands its global presence. By obtaining exclusive rights for 20 years, the company has shown a strong commitment to the development of next-generation cancer treatments. This achievement highlights ALBT’s focus on innovation and strategic growth in the quickly evolving precision medicine space.
